Host: Rabbit
Target Protein: P53 proteinwt-p53
Immunogen Range: 251-310/393
Clonality: Polyclonal
Isotype: IgG
Entrez Gene: 7157
Swiss Prot: P04637
Source: KLH conjugated synthetic peptide derived from human P53
Purification: Purified by Protein A.
Storage Buffer: Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.
Storage Condition: Store at 4°C for 12 months.
Background: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
Conjugation: ALEXA FLUOR® 647
Excitation/ Emission: 650nm/665nm
Size: 100ul
Concentration: 1ug/ul
Applications:
FCM(1:20-100)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
Cross Reactive Species:
Human
Mouse
Rat
Predicted Cross Reactive Species:
Cow
Sheep
Pig
Horse
Rabbit
For research use only. Not intended for diagnostic or therapeutic use.
- Chen, Jie, et al. "Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis." BMC cancer 12.1 (2012): 464.Read more>>
- Wang, Chao, et al. "Hypoxia inhibits myogenic differentiation through p53-dependent induction of Bhlhe40." Journal of Biological Chemistry (2015): jbc-M115.Read more>>
- Hong, Haizheng, et al. "Developmental toxicity of three hexabromocyclododecane diastereoisomers in embryos of the marine medaka Oryzias melastigma." Marine pollution bulletin (2015).Read more>>
- Celik‐Ozenci, C., et al. "Inhibition of poly (ADP‐ribose) polymerase may have preventive potential for varicocoele‐associated testicular damage in rats." Andrology (2016).Read more>>
- Sukohar, Asep, and Mohammad Kanedi. "Mucoxin (Acetogenin) Induce Expression of Pro-Apoptosis Proteins, Bax and P53, in T47D Breast Cancer Cells." Biomedical and Pharmacology Journal 10.2 (2017): 641-649.Read more>>
- Uchiumi et al. Characterization of the 5'-flanking region of the human TP53 gene and its response to the natural compound, Resveratrol. (2016) J.Bioche. 159:437-47Read more>>
- Celik-Ozenci et al. Inhibition of poly(ADP-ribose) polymerase may have preventive potential for varicocoele-associated testicular damage in rats. (2017) Andrology. 5:362-369Read more>>
- Liu F et al. Bioinformatic and experimental findings to indicate anti-cancer targets and mechanisms of calycosin against nasopharyngeal carcinoma. Research Square;12 February 2020.Read more>>
- Muhammad T et al. Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer. J Cancer Res Clin Oncol. 2020 Feb 22. Read more>>
- Tan J et al. Integrative findings indicate anti-tumor biotargets and molecular mechanisms of calycosin against osteosarcoma. Biomed Pharmacother. 2020 Jun;126:110096.Read more>>
Image kindly submitted by Piotr Mamczur from Wroclaw University. Immunofluorescent localization of p53 protein in mouse squamous cell cancer (KLN-205 cell line) with BS-0033R antibody (1:50) and FITC-labeled secondary antibodies (1:2000). The nuclei were stained with DAPI.
A549 cells were fixed with 4% PFA for 10min at room temperature,permeabilized with 90% ice-cold methanol for 20 min at -20℃, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with P53 protein(wt-p53) Polyclonal Antibody(bs-0033R)at 1:100 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2%BSA in PBS, followed by secondary antibody incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).
Tissue/cell: A431 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (P53 protein(wt-p53)) polyclonal Antibody, Unconjugated (bs-0033R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
Tissue/cell: A549 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (P53 protein(wt-p53)) polyclonal Antibody, Unconjugated (bs-0033R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.